Document Server@UHasselt >
Research publications >
Please use this identifier to cite or link to this item:
|Title: ||PREDICTION OF EARLY RESPONSE TO ANTI-TNF THERAPY AND DISEASE ACTIVITY STATE USING THE ANKYLOSING SPONDYLITIS DISEASE ACTIVITY SCORE|
|Authors: ||Vastesaeger, N.|
Rahman, M. U.
van der Heijde, D.
|Issue Date: ||2011|
|Publisher: ||OXFORD UNIV PRESS|
|Citation: ||RHEUMATOLOGY, 50. p. 144-144|
|Abstract: ||Background: We previously reported that in the ASSERT and GO-RAISE studies, BASDAI50 response can be accurately predicted with a combination of baseline characteristics. This analysis compares the accuracy of predicted response rates and disease activity as measured by different assessments including the ankylosing spondylitis disease activity score (ASDAS). Methods: The ASSERT and GO-RAISE trial data were combined and baseline characteristics were used to predict the probability for achieving week 12 ASAS20, BASDAI50 and ASDAS major response and BASDAI and ASDAS scores at week 12. Univariate analyses identified baseline predictors for response. Variable associations were explored using Spearman correlation analysis. A stepwise selection procedure using logistic regression, ROC and correlation analyses was used to select a final set of predictors. Logistic regression was used to calculate the predicted week 12 BASDAI and ASDAS scores and the probability of week 12 response to anti-TNF or placebo respective to combined selected predictors at baseline. The accuracy of prediction between the different assessments was compared using ROC analyses and R-square. Results: 479 AS patients (NY modified criteria) treated with anti-TNF and 156 patients treated with placebo with continued conventional, with BASDAI and spinal pain assessment 4 were included.
Age (mean 39.5; SD 11.3 yrs), BASFI, (mean 5.4; SD 2.2 cm), Berlin
enthesitis-score (mean 2.4; SD 2.9), therapy (anti-TNF or placebo),
CRP (mean 2.1; SD 2.4 mg/dL) and HLA-B27 genotype [(þ) or (-)] were
retained as final predictors of response. The area under the ROC curve
of the model which included the six selected predictors (log transfer of
CRP values) and interactions between predictors was 0.85, 0.79, and
0.75 and the R-square was 0.43, 0.33, and 0.24 for week 12 ASDAS
major response, BASDAI50 response and ASAS20 response, respectively.
This indicates good accuracy for prediction of BASDAI50
and ASDAS major response and fair accuracy for ASAS20 response.
The R-squares of 0.49 and 0.27 for ASDAS and BASDAI scores
respectively, indicate that the week 12 disease activity measured by
ASDAS could be more reliably predicted.
Conclusions: Elevated CRP, lower age, lower enthesitis score, lower
BASFI, and presence of HLA-B27 genotype are associated with a
better treatment response at week 12 in ASSERT and GO-RAISE. The
values of these characteristics at baseline allow calculating the
predicted response rates and future disease activity of an individual
patient. The accuracy of predicting ASDAS and ASDAS response is
good and higher than that of other assessments.|
|Notes: ||[Vastesaeger, N.] Merck & Co Inc, Med Affairs, Whitehouse Stn, NJ USA. [Wang, Y.] Merck & Co Inc, Global & Sci Med Publicat, Whitehouse Stn, NJ USA. [Inman, R.] Univ Toronto, Toronto, ON, Canada. [Deodhar, A.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Hsu, B.; Rahman, M. U.] Centocor Res & Dev Inc, Immunol, Malvern, PA USA. [Rahman, M. U.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA. [Dijkmans, B.] Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands. [Braun, J.] Rheumazentrum Ruhrgebiet, Herne, Germany. [Geusens, P.] Univ Hasselt, Hasselt, Belgium. [Sieper, J.] Rheum Charite Hosp, Berlin, Germany. [van der Heijde, D.; ASSERT ] Leiden Univ, Med Ctr, Leiden, Netherlands.|
|ISI #: ||000289163800374|
|Type: ||Journal Contribution|
|Appears in Collections: ||Research publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.